06132.HK
HJ Science Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 45.16
+4.34%Income statement
| Metric | 2025 |
|---|---|
| Revenue | |
| Total Revenue | 16.2M |
| Cost of Revenue | — |
| Gross Profit | 16.2M |
| Operating Expenses | |
| R&D Expense | 136.4M |
| SG&A Expense | 35.0M |
| General & Admin Expense | 35.0M |
| Selling & Marketing Expense | — |
| Other Expenses | — |
| Total Operating Expenses | 171.4M |
| Cost and Expenses | 171.4M |
| Operating Income (EBIT) | (155.3M) |
| Non-Operating | |
| Interest Income | — |
| Interest Expense | — |
| Net Interest Income | (52.0K) |
| Other Non-Op Income/Expense | (12.0M) |
| Non-Operating Income (excl Interest) | — |
| EBT (Pre-Tax Income) | (167.2M) |
| Income Tax Expense | 5.0K |
| Bottom Line | |
| Net Income | (167.2M) |
| Earnings from Cont. Ops | (167.2M) |
| Earnings from Discont. Ops | — |
| Bottom Line Net Income | (167.2M) |
| Per Share | |
| Basic EPS | (HK$2.83) |
| Diluted EPS | (HK$2.83) |
| Revenue Per Share | HK$0.27 |
| Shares | |
| Basic Shares Outstanding | 59.2M |
| Diluted Shares Outstanding | 59.3M |
| Profitability Metrics | |
| EBITDA | (152.9M) |
| D&A | 2.4M |
| EBIT | (155.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026